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Abstract
Delivery of vaccines into the skin provides many advantages over traditional parenteral vaccination and is a promising
approach due to the abundance of antigen presenting cells (APC) residing in the skin including Langerhans cells (LC) and
dermal dendritic cells (DDC). However, the main obstacle for transcutaneous immunization (TCI) is the effective delivery of
the vaccine through the stratum corneum (SC) barrier to the APC in the deeper skin layers. This study therefore utilized
microneedles (MN) and a lipid-based colloidal delivery system (cubosomes) as a synergistic approach for the delivery of
vaccines to APC in the skin. The process of vaccine uptake and recruitment by specific types of skin APC was investigated in
real-time over 4 hours in B6.Cg-Tg (Itgax-EYFP) 1 Mnz/J mice by two-photon microscopy. Incorporation of the vaccine into a
particulate delivery system and the use of MN preferentially increased vaccine antigen uptake by a highly motile
subpopulation of skin APC known as CD207+ DC. No uptake of antigen or any response to immunisation by LC could be
detected.
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Introduction
Transcutaneous immunization (TCI) is a novel approach to
deliver peptide, proteins, DNA or viral particulate vaccines into
the skin to the abundant resident antigen presenting cells (APC)
such as Langerhans’s cells (LC) in the epidermis and dermal
dendritic cells (DDC) in the dermis. LC are distributed throughout
the epidermis and make up approximately 3–5% of the total cells
present [1] and have been reported to be regulators of both
tolerance and immunity [2]. DDC reside in the dermis and are
assumed to be key regulators of cutaneous adaptive immune
responses [3]. LC have traditionally been discriminated from
DDC by their location, the presence of Birbeck granules and their
high langerin (CD207+) expression [4]. However CD207+
expression has also been observed on DDC populations [5]. It
has been reported that these CD207+ DC are involved in cross-
presentation of antigens and can potentially stimulate antigen-
specific cytotoxic T lymphocyte (CTL) and T helper 1 cell (Th1)
immune responses [6,7,8] whereas CD2072 DDC were found to
induce a primarily CD4+ T cell response [9].
The major barrier for transcutaneous delivery of vaccines is the
outer protective layer of skin; the stratum corneum (SC). One of
the most common methods for enhancing vaccine permeation into
skin is the utilization of lipid vesicles [10] for example, cubosomes
[11]. Cubosomes are a dispersion of the cubic liquid crystalline
phase that retain the unique nanostructure of the parent cubic
phase; a highly twisted, continuous lipid bilayer and two congruent
non-intersecting water channels [12]. It has been reported that the
penetration enhancing effect of cubosomes is due to the lipids of
the particles forming a mixture with the lipids of the SC due to
their similar cubic phase structure and thereby fluidizing the SC
[13,14]. Cubosomes have been used successfully for the transder-
mal delivery of several drugs including indomethacin [14] and
hydrophilic plant extracts from Berberis koreana [15].
Another approach to overcoming the barrier provided by the
SC is to transiently perforate skin using microneedles (MN). The
short needles (less than 1 mm) in microneedle arrays disrupt the
SC, forming transient micro-channels that facilitate the delivery of
drugs [16], macromolecules [17,18] or vaccines [18,19] to the
deeper tissue. MN possess the potential to revolutionise the field of
vaccine delivery due to low manufacturing and product distribu-
tion costs [20], the fact they may not require skilled vaccine-
administration expertise, are painless to use [21] and will likely
have wide public acceptance [22]. Numerous studies have
investigated the ability of MN to deliver vaccines into the skin
[23,24,25] demonstrating the effectiveness of this approach as
compared to subcutaneous [26,27] or intramuscular vaccination
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[24,28]. In this study, a combination of MN and cubosomes was
therefore employed to overcome the barrier imposed by the SC
and enhance vaccine delivery into the skin.
While TCI has been investigated by a number of different
research groups, no studies have been carried out investigating the
dynamics of interactions between vaccines and APC at the cellular
level in real-time and in living animals. As it has been reported
that the different APC subsets in the skin may promote
qualitatively different immune responses, such interactions may
be crucial in determining the outcome of TCI and by
understanding these interactions it may be possible to design
more effective vaccines. This lack of such data is due to the
limitations of traditional imaging techniques such as fluorescent
microscopy and confocal laser scanning microscopy (CLSM)
which have a reduced ability to visualize into deep turbid tissue
[29,30]. However, a combined approach utilizing advanced
fluorescent labelling techniques and two-photon microscopy
(2 PM) has been widely used in structural and functional studies
of deep tissue [31]. Another key advantage of 2 PM over CLSM is
reduced photo-breaching at out-of-focal plane regions [32].
Additionally, second harmonic generation (SHG) occurs concur-
rently with 2 PM [33]. SHG is not generated from absorption but
from hyper-Rayleigh scattering by the two low energy photons
[34]. SGH occurs when light interacts with asymmetric macro-
molecular arrangements such as collagen fibres [35]. Consequent-
ly, the overall purpose of this study was to visualize TCI in real-
time with particular emphasis on interactions with different APC
populations in the skin using 2 PM and also to examine the ability
of a combined approach of cubosomes and MN to induce immune
responses.
Materials and Methods
Ethics Statement
All experiments were approved by the Animal Ethics Commit-
tee, University of Otago or by the Animal Experimental
Committee of Osaka University.
Materials
Phytantriol was purchased from A & E Connock (Hampshire,
England). Poloxamer 407 (LutrolH F127) was obtained from BASF
(Ludwigshafen, Germany) and 1,2-propandiol (Propylene Glycol,
purity$99.5%) from Merck (Darmstadt, Germany). CD8 Oval-
bumin peptide (SIINFEKL, OVA257–264) and CD4 Ovalbumin
peptide (ISQAVHAAHAEINEAGR, OVA323–339) and 5(6)-tetra-
methylcarboxy rhodamine-labelled OVA257–264 (TMR-SIIN-
FEKL) was purchased from Mimotopes (Clayton, Australia).
Monophosphoryl Lipid A from Salmonella Minnesota RE 595 was
purchased from Sigma-Aldrich (Missouri, USA). Purified saponin
(Quil-A) was purchased from Brenntag Biosector (Frederikssund,
Denmark). All other chemicals were of analytical grade.
Microneedle Arrays
Microneedle arrays fabricated from biocompatible polycarbon-
ate polymers using an injection moulding process were supplied by
Professor James Birchall (School of Pharmacy and Pharmaceutical
Sciences, Cardiff University, UK). The 13-needles (670-mm/6
needles, 520-mm/6 needles and 335-mm/1 needle) were arranged
in concentric circles [36].
Figure 1. Two-photon microscopy (2 PM) visualization of Langerhans and dermal dendritic EYFP-CD11c+ cells in mouse skin. (A) XZ
cross-sectional image of intact skin. XY images of (B) skin surface autofluorescence, (C) Langerhans cells (LC) localised in the epidermis and (D) dermal
dendritic cells (DDC) in the dermal layer. Scale bar is 50 mm.
doi:10.1371/journal.pone.0089503.g001
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Figure 2. Impact of TCI on LC. Two-photon microscopy (2 PM) visualization of the distribution of LC (green) and formulation (red) in the epidermis
of unimmunized mice (A, B) or following application of (C, D) TMR-SIINFEKL-loaded cubosomes for 40 min (A, C) and 240 min (B, D). Images are
representative of groups of three mice. Scale bar is 100 mm. (E) The number of LC/mm2 in the epidermis in untreated controls (control) or following
the application of aqueous TMR-SIINFEKL (peptide), rhodamine-labeled cubosomes (rhodamine) and TMR-SIINFEKL-loaded cubosomes (cubosomes)
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Cubosome Preparation
Antigen/adjuvant-loaded cubosomes with a size of 158 to182
nm were formulated using the lipid precursor method [37]. Briefly,
phytantriol, poloxamer 407, propylene glycol and MPL were
weighed into a 20-mL scintillation vial and dissolved in 5 mL
chloroform. Rhodamine-labeled cubosomes were prepared by
adding octadecyl rhodamine B chloride (R-18, Invitrogen
Molecular Probes, OR, USA) into the scintillation vial prior to
preparation of the cubosomes with a mass ratio of dye to lipid of
1:2000. Chloroform was evaporated under a stream of nitrogen at
45uC. The concentrated actives solution (0.8 mg/20 mL Quil-A
(QA) and 2 mg/20 mL peptide) and glass beads were added and
mixed by shaking until visually homogenous. Milli-Q water (45uC)
was gradually added into the scintillation vial to a final volume of
1 mL while vortexing for 10 min. Peptide entrapment was
approximately 23% as previously reported [38].
Mice
For 2 PM experiments, 6–10 week old male and female B6.Cg-
Tg (Itgax- Enhanced Yellow Fluorescent Protein) 1 Mnz/J mice
originally purchased from The Jackson Laboratory (Maine, USA)
were maintained under specific pathogen-free conditions at the
Osaka University animal facility under an approved protocol from
the Animal Experimental Committee of Osaka University. For
other studies, male C57BL/6, 6–8 weeks old were utilized, bred
and maintained under specific pathogen-free condition at the
HTRU, Dunedin, New Zealand.
Two-photon Microscopy
Prior to performing the imaging experiments, the hair on the
lower back of mice was removed with an electronic hair clipper.
Any remaining hair was removed using depilatory cream (NairH,
Carter Products, NY). The skin was wiped with moist cotton to
remove all the depilatory cream.
The imaging system was an A1RMP multiphoton microscope
(Nikon, Japan) driven by a Chameleon Vision II Ti:Sapphire laser
(Coherent, CA, USA) tuned to 920 nm with an inverted
microscope equipped with a 206 oil immersion objective (CFI-
Plan-Fluor, N.A. 0.75, Nikon). Laser power at the acquisition area
was 25 mW. Fluorescent probes were detected through bandpass
emission filters. Formulations were detected using a 561/25 nm
filter and collagen using a 440/25 nm filter. Images were acquired
from 20 to 45 z-planes, spaced 5 mm apart every 5 min for up to
240 min. Snapshot images were acquired using scanning averages
of 2 scans. Raw imaging data was processed with Imaris software
(Bitplane AG, Zu¨rich, Switzerland). To assess vaccine penetration,
2 PM images were captured in the XZ-plane using the ortho slicer
function in the Imaris software. The microscope system was
enclosed in an environmental compartment in which anesthetised
mice were warmed by heated air.
Formulations (diluted 1:20 in sterile MilliQ-water) were applied
onto the skin with excess formulation being removed after 2 min
by capillary action using a tissue. For experiments utilizing MN,
the MN were applied manually to the prepared skin before
application of formulations. A glass slide was attached to the skin
using tissue glue (Vetbond Tissue Adhesive, 3 M Animal Care
Products, MN, USA). Mice were then placed on a custom-
designed stage. Mice were anesthetised with isoflurane (Escain; 2%
vaporized in 100% oxygen) throughout the experimental period.
In vivo Uptake of Formulations by Skin LC and DC
The immunization procedures were similar to that described in
the previous section. However, the testing area was protected by
paper and then covered with an occlusive dressing and the cage
was covered to protect from light. After euthanasia, a section of the
immunization site was rinsed with PBS to remove residual
formulation and then harvested. The skin was macerated and
incubated at 37uC for 1 hr in collagenase type IA (C9891, Sigma-
Aldrich, St. Louis, MO) digestion buffer. A single cell suspension
was fixed in 8% paraformaldehyde at room temperature. Cells
were then permeabilized using saponin (S-7900, Sigma-Aldrich,
St. Louis, Mo) buffer and incubated with anti-CD16/CD32 before
being stained with anti-CD207-Alexa Flour 488 (eBioscience, San
Diego, CA) for 30 minutes followed by washing and staining with
anti-CD11c-APC, anti-CD11b-PE-Cy7 (BD PharMingen, San
Diego, CA) and anti-F4/80- Brilliant Violet 421 (Biolegend, San
Diego, CA). Cells were then analysed using a FACSCantoTM II
flow cytometer (BD Biosciences, San Jose, CA). Data was analysed
using FlowJo 7.6 analysis software (Tree Star, Inc., Oregon, USA).
Transcutaneous Immunization
Adoptive transfer was performed as described previously [39].
Briefly 46106 lymphocytes from OT-I and OT-II were injected
into the tail vein of each recipient C57BL/6 mouse a day prior to
TCI. The following day the C57BL/6 mice were anaesthetised
and were close clipped. Self-adhering foam base (RestonTM, 3 M),
was attached on the skin of mouse to form a reservoir. Vaccine
formulations, 100 mL containing 100 mg of CD4+ peptide, 100 mg
of CD8+ peptide, 40 mg of QA and 20 mg of MPL formulated in
cubosomes (2 mg of lipid) or in Milli-Q water or cubosomes
containing adjuvants only (control) were applied on the skin inside
the reservoir which was then covered with an occlusive dressing
(Opsite-FlexifixTM, Smith & Nephew Medical Limited and
BlendermTM, 3 M). For experiments utilizing MN, the micronee-
dle array was applied manually to the prepared skin before
application of formulations. The reservoirs were removed after
6 hr. The immunization procedure was repeated at day 14 and
then at day 18 the mice were sacrificed and regional lymph nodes
taken. Single cell suspensions were then prepared from all
harvested lymphoid tissues. Aliquots of single cell suspensions of
lymphocytes were incubated with anti-CD16/CD32 before being
stained with anti-CD4-V500, anti-CD8-PE-Cy7, anti-Va2-PE and
anti-Vb5-biotin. This was followed by staining with SA-Percp-
Cy5.5 and propidium iodide. Antibodies and propidium iodide
were purchased from BD Biosciences Pharmingen (California,
USA). Cells were analysed on a FACSCantoTM II (BD Biosci-
ences) and data was analysed using FlowJo 8.6 (Tree Star Inc).
Interferon-c Assay
A 100 mL aliquot of a single cell suspension of 26106
lymphocytes/mL was plated in triplicate a 96-well round
bottomed plate for restimulation with anti-CD3 (10 mg/mL),
OVA (20 mg/mL) and IL-2 (2 ng/mL) or IL-2 alone (2 ng/mL).
The plates were incubated for 3 days in a CO2 incubator (5% CO2
at 37uC) (HERAcell incubator, Heraeus, Hanau, Germany). On
day 4, 100 mL of the cell culture supernatant was removed and
stored at 220uC until analysis. Interferon c was measured using a
BDTM Cytometric Bead Array (CBA) Mouse T Cell Cytokine Kit
according to the manufacturer’s instructions.
in the presence and absence of MN for 40 and 240 min. Cells were quantified from three randomised images from one mouse per group in three
independent experiments. Data presented are the mean+SD.
doi:10.1371/journal.pone.0089503.g002
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Figure 3. Impact of TCI on DDC. Two-photon microscopy (2 PM) visualization of DDC (green) and collagen (blue) in the dermis in unimmunized
mice (A, B) or following application of MN and TMR-SIINFEKL-loaded cubosomes (C, D) for 40 min (A, C) and 240 min (B, D). Images are representative
of groups of three mice. Scale bar is 200 mm. (E) The number of DDC/mm2 in untreated controls (control) or following the application of aqueous
Imaging Transcutaneous Immunization
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TMR-SIINFEKL (peptide), rhodamine-labeled cubosomes (rhodamine) and TMR-SIINFEKL-loaded cubosomes (cubosomes) in the presence and
absence of MN at 40 and 240 min. Cells were quantified from three randomised images from one mouse per group in three independent
experiments. Data presented are the mean+SD. ***P,0.001 compared to the control group (two-tailed unpaired Student’s t-test).
doi:10.1371/journal.pone.0089503.g003
Figure 4. Formulation-DDC colocalization. Two-photon microscopy (2 PM) visualization of collagen (blue), DDC (green) and vaccine (red) in the
dermis of untreated mice (A) or 40 min following application of an aqueous TMR-SIINFEKL mixture (B, E), rhodamine-labelled cubosomes (C, F), or
TMR-SIINFEKL-loaded cubosomes (D, G) to intact (B-D) or MN pretreated (E-G) skin. Cross sections (XZ, far left) and 3-D images (XYZ) are shown as well
as merged images and scatter 2D plots of voxel intensities (far right panel) in the red and green channels for selected DC. Scale bar is 100 mm.
doi:10.1371/journal.pone.0089503.g004
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Data and Statistical Analysis
Data analysis was carried out using Microsoft Excel, Version
2010. The results are expressed as mean 6 SD and mean6 SEM.
GraphPad Prism Version 5.0 was used to examine the statistically
significant differences using the two-tailed unpaired Student’s t-test
or the one-way analysis of variance (ANOVA) followed by Tukey’s
pairwise comparison.
Results
DDC, not LC, Respond Initially to Transcutaneously
Applied Antigen
The two main populations of skin CD11c+ APC, the LC and
DDC, reside in distinct locations (Fig. 1. and Movie S1). Two
criteria were used to distinguish LC from DDC; location within
the skin and physical morphology. LC were widespread in the
epidermis [40] which could be clearly identified by the absence of
collagen fibres (Fig. 1). Figure 1 B, C and D are XY images taken
at the skin surface, through the epidermis and through the dermis,
respectively. The unique morphology of LC, with their dendrites
extending from the cell body, is clearly visible in Fig. 1 C. DDC
had no visible dendrites and were found in the dermis (Fig. 1 D).
After MN insertion, the epidermis and the dermis were
transiently disrupted (Movie S2). Due to the technical require-
ments for application of formulations and set-up of the
microscope, the first images were taken 30–40 minutes after
TCI. Formulation was observed to penetrate from the micro-
channel over time and DDC were found in close proximity to
areas of formulation (Movie S2 and [38]).
The physical morphology and number of the LC in intact and
MN pretreated skin before and after immunisation was examined
(Fig. 2). The cells were non-motile (determined from time series
analysis over 4 hours) and had 4–5 dendrites projecting from the
body of the cell. LC density in untreated skin was determined to be
approximately 980 cells/mm2. Upon application of the vaccine to
the skin, no change in LC morphology or density could be seen
(Fig. 2 D and E) over the time period investigated (40–240
minutes). By 240 min fluorescence of the LC in the skin was
reduced in all samples (Fig. 2 B and D) due to photobleaching.
Pretreatment of skin with MN before immunization similarly did
not impact on LC density (Fig. 2 E.).
Subsequently, the ability of LC to capture formulation was
examined. Detailed analysis of images using ImarisColoc (Bit-
plane) was carried out to quantify LC-antigen colocalization.
Pearson’s coefficient was used to describe the correlation of the
intensity distribution of the green fluorescence of the LC and the
red fluorescence from the vaccine formulations. A Pearson’s
coefficient of 1 indicates a significant positive correlation; 0
indicates no significant correlation and 21 indicates complete
negative correlation. Values between 0.5 and 1 would indicate
formulation-cell colocalization [41]. The calculated Pearson’s
coefficient of LC from all vaccine experiments was zero
throughout the experimental period. It was therefore established
that no detectable formulation-LC colocalization occurred.
DDC were easily distinguishable in the dermis of CD11c+-
EYFP transgenic mice. The size of DDC could not be precisely
measured in these highly motile cells as they were constantly
changing shape and moving both horizontally and vertically
through the skin, squeezing between other cells and making
contact with other DDC (Movie S3). An increase in the number of
DDC was found in the skin of all mice treated with formulations
when compared to unimmunized skin (control) at 40 min and
240 min following TCI (Fig. 3). However, this was significant only
for mice immunized using TMR-peptide in cubosomes 240 min
following immunization (P,0.001). MN pretreatment resulted in a
significant increase in DDC at both 40 and 240 min post-
application of TMR-peptide in cubosomes (P,0.001).
Formulation-DDC colocalization was then examined by 2 PM.
XYZ sections of the dermis (Fig. 4) were examined in detail
40 min after TCI. Formulation of the vaccine into cubosomes
resulted in the highest levels of antigen being detected in dermis.
Antigen-DDC colocalization was examined in selected cells (Fig. 4
far right column) through 2D plots of voxel intensities. Areas of
high fluorescence intensity (due to autofluorescence of skin
appendages) were avoided. This analysis confirmed antigen (red
channel)-DDC (green channel) colocalization. Quantitative anal-
ysis of DDC-formulation colocalization was performed and
expressed in terms of a Pearson’s correlation coefficient (Fig. 5)
against time (40–240 min). The TMR-peptide in cubosome
formulation achieved a Pearson’s coefficient above 0.5 after
application to both intact and MN pretreated skin at all time
points assessed.
Interestingly, DDC could also be found extending into the
epidermis in XZ cross-sectional images (Fig. 6 and Movie S4)
capturing and taking up formulations from the upper layers of the
skin.
Minor Population of Langerhin+DDC Takes up Antigen
Following TCI
APC were isolated from skin immunized transcutaneously in the
presence and absence of MN pretreatment or from unimmunized
control mice. Skin DC were identified based on CD11c expression
and were then gated based on CD207 and CD11b expression
(Fig. 7 A) into LC (CD207hi, CD11bhi), langerin+ DDC (CD207hi,
CD11blo [1]) and langerin2 DDC (CD11b hi/lo CD207 lo [7,42]).
LC comprised approximately 8–10% of the isolated skin DC (Fig. 7
C). A small population of langerin+ DC was also found in the full-
thickness skin (3–4% of total DC in the skin) in agreement with
previously published studies [43]. The largest population of DC in
the skin were the Langerin2 DDC population (,70%). Following
formulation application, while there was no significant change in
the number of any of the DC subsets (Fig. 7 C), uptake of
Figure 5. DDC-formulation colocalization. Pearson’s correlation
coefficient calculated from skin treated with: an aqueous peptide
mixture (N), rhodamine-labeled cubosomes (m) and TMR peptide-
loaded cubosomes (&). The black and red colour represent intact and
MN pretreated skin respectively. Unimmunized intact skin served as
control (#). Cells were quantified from three randomised images from
one mouse in three independent experiments. Data presented are the
mean+SEM (n= 9).
doi:10.1371/journal.pone.0089503.g005
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fluorescent peptide by skin DC (Fig. 7 B and D) was detected in
the minor langerin+ DDC subset in mice treated with MN and
peptide-loaded cubosomes (P,0.05). Consistent with the 2 PM
antigen-DC colocalization studies, no uptake by LC was detected.
The ability of TCI with the OVA CD4 and CD8 minimal
peptide epitopes either delivered in water or in cubosomes, with or
without MN pretreatment to induce immune responses following a
prime-boost regime was assessed (Fig. 8). The number of antigen-
specific CD4+ T cell in the lymph nodes (Fig. 8 A) was low and not
above that found in control mice immunised with a control
cubosome formulation containing the adjuvants but no antigen
(P.0.05). Mice immunized transcutaneously with peptide in water
or peptide formulated in cubosomes had a measureable antigen-
specific CD8+ T cell expansion as compared to the control
cubosome formulation (Fig. 8 B). The combination of pretreat-
ment with MN before the application of the formulation did not
significantly enhance the antigen specific expansion of CD8+ T
cells as compared to formulation applied to intact skin. Similar
results were found in a functional assay where the ability of lymph
node cells to produce IFN-c upon restimulation with antigen was
examined. Lymphocytes from mice immunized using MN and
either cubosome or peptide in water produced significant levels of
antigen specific IFN-c (Fig. 8 C). However when the formulations
were applied to intact skin only lymphocytes from mice immunised
with cubosomes produced significant levels of IFN-c (P,0.05).
Discussion
The aim of this study was to investigate the interface between
TCI and the immune system using 2 PM and flow cytometry. TCI
was accomplished using a lipid nanocarrier in combination with
MN. Cubosomes were chosen as the carrier due to their ability to
promote penetration of vaccine into the skin in vitro [11]. MN were
used to temporarily disrupt the skin barrier and improve vaccine
delivery to the epidermis and the dermis where LC and DDC
reside. The synergistic effect of combining lipid particles and MN
on immunological responses has been previously reported by
Hirschberg et al. [44]. They indicated that the induction of
antibody responses occurred only when mice were immunized
with a combined approach using both vesicles and MN. Zaric et al.
[45] also reported that robust immune responses were generated
Figure 6. Two-photon microscopy (2 PM) visualization of DDC uptake of antigen. (A) Orthogonal views (XY, XZ, YZ) through a DDC
illustrating colocalization of DDC (green), TMR-SIINFEKL (red) and collagen (blue). Colocalization is visible as a yellow colour and orange represents
the leakage of intense red fluorescence into the green channel. (B–C) 3D images of the DDC from (A). All channels are shown in (B), blue has been
dropped out in (C) and both blue and green in (D). TMR-SIINFEKL uptake by the DDC is shown in (D) indicated by arrow. Scale bar is 20 mm.
doi:10.1371/journal.pone.0089503.g006
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by utilizing MN to deliver vaccine-loaded poly-D-L-lactide-co-
glycolide (PGLA) nanoparticles to the skin APC.
LC present in the epidermis are the first APC that transcuta-
neously applied vaccine antigens should encounter. However in
the early stages of immunization examined here, LC were not
found to be motile, the number of LC was not altered in response
to the application of formulation and no antigen-LC colocalization
could be detected either by 2 PM or flow cytometry. Sen et al. [46]
similarly found that LC were completely immotile until 48 hr after
the injection of adjuvants such as CpG and LPS and even then
only a subpopulation of LC (approximately 15%) moved at a very
low velocity. Studies of TCI using MN in human skin explants
have also shown that LC responses occur over 24 to 48 hours
[18,47]. The role of LC in the initiation of immune responses is
conflicting and incompletely understood. While LC have been
shown to be able to extend their dendrites into the SC layer to
capture antigen [48] and to be able to efficiently take up soluble
antigen [49] other studies have shown they are not involved in
priming immune responses in skin but are perhaps involved in
tolerance [2]. The fact that LC do not appear to be involved in the
immediate response in interesting and is perhaps suggestive of a
more regulatory role.
TCI using peptide loaded-cubosome formulations was however
found to have an impact on DDC recruitment and this occurred
earlier if MN pretreatment was employed. Two adjuvants with
different immune activatory activities were included in the
formulation in order to optimize immune stimulation. QA is a
hydrophilic TLR-independent adjuvant that has recently been
reported to activate the NLRP3-inflammasome [50] while MPL is
a lipophilic TLR-4 ligand [51,52,53]. Cubosomes were chosen as
the delivery system as their biphasic structure facilitates entrapp-
ment of both adjuvants and the antigen. In addition particulate
delivery systems have been shown themselves to activate the
inflammasome [54]. Activation of the NALP3-inflammasome
leads to release of IL-1b, a potent proinflammatory cytokine,
which results in the recruitment of immature DC [55,56]. TLR-4
agonists activate NF-kB, a pro-inflammatory gene transcription
regulator, which results in the up-regulation of the co-stimulatory
molecules CD80 and CD86 [57] and the production of IP-10/
CXCL10 chemokines responsible for Th1 recruitment [58]. In this
study we observed DC recruitment occurring 40 min after
immunization with TMR-peptide in cubosomes (when MN were
utilized) and within 4 hr when the vaccine was applied to the
intact skin. This only occurred if the vaccine antigen and adjuvant
were loaded into cubosomes, not when they were applied as an
aqueous mixture. Previous investigations into the mechanism of
vaccine permeation into skin revealed that the lipophilic cubo-
somes are retained in the microchannels formed by MN creating
an immunestimulatory depot and also facilitating the movement of
unentrapped peptide antigen and adjuvant into the deeper layers
of the skin to interact with APC [38]. The kinetics of the response
is similar to that found following topical application of measles
virus nucleoprotein onto mucosal tissue where DC were found to
be recruited rapidly, peaking at 2 hr, while DC migration to the
draining lymph node took place over 24 hr [59]. Interestingly,
rhodamine labelled cubosomes containing the adjuvants MPL and
QA but no antigen did not significantly effect DDC recruitment.
This requirement for antigen suggests that DC-T cell interactions
are required for the observed DDC recruitment. The skin contains
Figure 7. Antigen uptake by skin APC. (A) Representative dot plots
showing gating for flow cytometric analysis. CD11chi DC cells were
selected and further gates determined on the basis of CD207 and
CD11b expression. (B) Representative histograms of the uptake of
vaccine; TMR-SIINFEKL (peptide), rhodamine-labeled cubosomes (Rho-
damine) or TMR peptide-loaded cubosomes (cubosomes) by Langerin+
DDC following TCI. The solid grey histograms are Langerin+ DDC from
unimmunised controls and the open histograms are Langerin+ DDC
from immunised mice. (C) Number of LC, Langerin+ DDC and Langerin2
DDC at 240 min in untreated control mice (control) or in mice
immunised with aqueous TMR-SIINFEKL (peptide), rhodamine-labeled
cubosomes (rhodamine) and TMR-SIINFEKL-loaded cubosomes (cubo-
somes) in the presence and absence of MN pretreatment. (D) Uptake of
antigen (median fluorescence intensity) by LC, Langerin+ DDC and
Langerin2 DDC at 240 min in untreated control mice (control) or in
mice immunised with aqueous TMR-SIINFEKL (peptide), rhodamine-
labeled cubosomes (rhodamine) and TMR-SIINFEKL-loaded cubosomes
(cubosomes) in the presence and absence of MN pretreatment. The
results of the antigen uptake are given as. Data are mean+SEM and are
representative of three independent experiments with 5 mice per
group. *P,0.05 (two-tailed unpaired Student’s t-test).
doi:10.1371/journal.pone.0089503.g007
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Figure 8. Immune responses stimulated by TCI. Number of transgenic Va2+Vb5+ CD4+ (A) and Va2+Vb5+ CD8+ (B) T cells in lymph nodes of
mice vaccinated with 100 mg of CD4+ peptide, 100 mg of CD8+ peptide, 40 mg of QA and 20 mg of MPL formulated in cubosomes (Cubosomes) or in
Milli-Q water (Water) or with cubosomes containing only MPL and QA (Control) in the presence and absence of MN pretreatment. (C) Production of
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large numbers of skin resident memory T cells [60] and naı¨ve T
cells [61]. It would be of interest to examine the interactions
occurring between DC and T cell subsets in the skin using 2 PM.
Antigen-DDC colocalization could be visualized by 2 PM and
confirmed by calculation of Pearson’s correlation coefficient, in
skin treated with TMR-peptide in cubosomes in the presence and
absence of MN pretreatment. Current dogma suggests that DDC
are unable to penetrate into the epidermis because of the barrier
provided by the epidermis-dermis tight junction [62], although it
has been reported that DC cluster around hair follicles and that
dendrites can penetrate the basement membrane to sample
antigen present in the epidermis [63]. Flow cytometry suggested
that it was the langerin+ DDC subset that was taking up antigen.
As the vaccine was not actively targeting these cells the preferential
uptake of the vaccine must be related to the phenotype or physical
location of this population of cells. Bursch et al [63] reported that
langerin+ DDC have been identified penetrating into the
epidermis therefore it may be that the physical location of these
cells results in the preferential uptake. This population of cells has
additionally been reported to trigger Th1 immune responses and
induce predominantly cellular immunity, including antigen-
specific CD8+ T cell [6]. It is possible that by utilizing MN the
vaccine is targeted to a different subset of APC than it would be if
applied to intact skin and that a qualitatively different immune
response is produced.
Immune responses to vaccines applied transcutaneously to mice
were examined and while there were perhaps some minor
differences in the responses induced by the vaccines, all vaccines
were able to stimulate weak but detectable responses. This is a
limitation of using mice to examine immune responses to vaccines
applied transcutaneously, as vaccination is much more effective
due to the thin SC (approximately 9 mm in mice and human
20 mm in humans [64]) and high number of hair follicles
(approximately 660/cm2 in mice and 11/cm2 in humans [65]).
An additional issue is the removal of hair by methods such as
plucking, shaving or through the use of a depillatory cream. All
these methods, including the depillatory cream used here, can act
to enhance vaccine penetration [66,67]. Therefore while mice are
an invaluable tool for investigating cellular interactions occurring
in the skin they are less useful for evaluating the immunological
activity of potential vaccine formulations.
In conclusion the use of a lipid based delivery system in
combination with MN can potentiate immune responses to
peptide antigens delivered transcutaneously by facilitating uptake
of vaccine by dermal dendritic cells. Further preclinical studies in
more appropriate animal models (for example miniature pigs) or
clinical studies in man will be necessary in order to determine the
full potential of such vaccine formulations.
Supporting Information
Movie S1 Two-photon microscopy (2 PM) visualization
of EYFP-CD11c+ in mouse skin. Collagen is shown as blue
fluorescence and green fluorescence represents stratum corneum
or hair follicle autofluorescence and EYFP-CD11c+ cells.
(MP4)
Movie S2 Transient formation of a microchannel and
penetration of vaccine following application of peptide
loaded cubosomes (shown in red) to MN pretreated
skin. A 3D image (top) and XZ cross sections (bottom) are shown.
Collagen is visible as blue fluorescence and green fluorescence
represents EYFP-CD11c+ cells. Bright yellow florescence is a result
of autofluorescence of hair follicles. EYFP-CD11c+ DDC can be
seen in close proximity to the vaccine formulation.
(MP4)
Movie S3 Rapid movement of DDC in normal skin.
Collagen is shown as blue fluorescence and green fluorescence
represents EYFP-CD11c+ cells.
(MP4)
Movie S4 Uptake of vaccine by DDC. A highly motile DDC
can be seen taking up vaccine from the epidermis. Peptide is visible
as red fluorescence, collagen is shown as blue fluorescence and
green fluorescence represents EYFP-CD11c+ cells. Areas of
antigen/DDC colocalization are yellow.
(MP4)
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